156 related articles for article (PubMed ID: 12570680)
1. Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease.
Ivorra C; Samyn H; Edo MD; Castro C; Sanz-González SM; Déez-Juan A; Andrés V
Curr Pharm Biotechnol; 2003 Feb; 4(1):21-37. PubMed ID: 12570680
[TBL] [Abstract][Full Text] [Related]
2. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.
Andrés V
Cardiovasc Res; 2004 Jul; 63(1):11-21. PubMed ID: 15194457
[TBL] [Abstract][Full Text] [Related]
3. CDKs and CKIs: molecular targets for tissue remodelling.
Nabel EG
Nat Rev Drug Discov; 2002 Aug; 1(8):587-98. PubMed ID: 12402499
[TBL] [Abstract][Full Text] [Related]
4. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human.
Lee YM; Sicinski P
Cell Cycle; 2006 Sep; 5(18):2110-4. PubMed ID: 16969111
[TBL] [Abstract][Full Text] [Related]
5. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
7. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Santamaria D; Ortega S
Front Biosci; 2006 Jan; 11():1164-88. PubMed ID: 16146805
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
9. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
[TBL] [Abstract][Full Text] [Related]
10. The cell cycle and cardiovascular diseases.
Boehm M; Nabel EG
Prog Cell Cycle Res; 2003; 5():19-30. PubMed ID: 14593697
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibitors: novel anticancer agents.
Mani S; Wang C; Wu K; Francis R; Pestell R
Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
[TBL] [Abstract][Full Text] [Related]
12. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibitors of cyclin-dependent kinases.
Knockaert M; Greengard P; Meijer L
Trends Pharmacol Sci; 2002 Sep; 23(9):417-25. PubMed ID: 12237154
[TBL] [Abstract][Full Text] [Related]
14. Impairment of rat postnatal lung alveolar development by glucocorticoids: involvement of the p21CIP1 and p27KIP1 cyclin-dependent kinase inhibitors.
Corroyer S; Schittny JC; Djonov V; Burri PH; Clement A
Pediatr Res; 2002 Feb; 51(2):169-76. PubMed ID: 11809910
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cellular proliferation by drug targeting of cyclin-dependent kinases.
Pérez-Roger I; Ivorra C; Díez A; Cortés MJ; Poch E; Sanz-González SM; Andrés V
Curr Pharm Biotechnol; 2000 Jul; 1(1):107-16. PubMed ID: 11467357
[TBL] [Abstract][Full Text] [Related]
16. Cyclin dependent kinases in cancer: potential for therapeutic intervention.
Canavese M; Santo L; Raje N
Cancer Biol Ther; 2012 May; 13(7):451-7. PubMed ID: 22361734
[TBL] [Abstract][Full Text] [Related]
17. Function of hybrid human-yeast cyclin-dependent kinases in Saccharomyces cerevisiae.
Bitter GA
Mol Gen Genet; 1998 Oct; 260(1):120-30. PubMed ID: 9829836
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
Pavletich NP
J Mol Biol; 1999 Apr; 287(5):821-8. PubMed ID: 10222191
[TBL] [Abstract][Full Text] [Related]
19. Anticancer therapeutic strategies based on CDK inhibitors.
Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative strategies for the treatment of vascular proliferative disease.
Andrés V; Castro C
Curr Vasc Pharmacol; 2003 Mar; 1(1):85-98. PubMed ID: 15320855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
